PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

BMS’ Zeposia hits the mark in ulcerative colitis

Bristol Myers Squibb’s oral S1P receptor modulator Zeposia hit both primary endpoints in a phase III trial as an induction and maintenance therapy in adult patients with moderate-to-severe ulcerative colitis (UC).

The True North study showed that Zeposia (ozanimod) demonstrated statistically significant and clinically meaningful results for clinical remission compared to placebo at induction at week ten (18.4% versus 6.0%) and in maintenance at week 52 (37.0% versus 18.5%).

Zeposia also met key secondary endpoints, including clinical response, endoscopic improvement and mucosal healing in induction at week ten and in maintenance at week 52.

In addition, significantly more patients treated with Zeposia compared to placebo achieved clinical response at week ten (47.8% versus 25.9%) and at week 52 (60.0% versus 41.0%), with consistent results across sub-analyses.

In patients with prior TNF-inhibitor exposure, clinical remission results favoured Zeposia over placebo, although the findings were not significant at week ten. A nominally statistically significant difference was observed for clinical response, however.

“These Zeposia True North results represent a meaningful achievement for patients living with ulcerative colitis, many of whom have an inadequate response or do not respond at all to currently available therapies,” said Mary Beth Harler, head of Immunology and Fibrosis Development, BMS.

“We look forward to working with health authorities to bring Zeposia to this patient population and remain committed to pursuing new scientific advances to help deliver transformational medicines for the gastroenterology community,” she added.

Zeposia was approved earlier this year for the treatment of adults with relapsing forms of MS, including relapsing-remitting MS (RRMS), active secondary progressive MS (SPMS) and clinically isolated syndrome (CIS).

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026